This is a summary of the European public assessment report (EPAR) for Cinryze. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cinryze.
Therapeutic Indication
### Therapeutic indication Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.
Therapeutic Area (MeSH)
ATC Code
B06AC01
ATC Item
c1-inhibitor, plasma derived
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| C1 inhibitor (human) | N/A | Human C1-esterase inhibitor |
EMA Name
Cinryze
Medicine Name
Cinryze
Aliases
N/ANo risk management plan link.
